<qa>  How many patients will receive three double-blinded non-injectable therapies?600 patients aged 30-80 who have been on stable doses of 2 classes of therapy not including the trial IMPs or GLP1-agonist for at least 3 months with HbA1c 58mmolmol 7.5 will receive three double-blinded third-line non-injectable therapies. On recruitment into the study participants will have underlying pathophysiology assessed in a mixed-meal tolerance test MMTT and samples will be collected for baseline analysis and storage for future biomarker analysis and discovery. Participants will then receive 16 weeks of each over-encapsulated blinded therapy in random order. 